Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

Stopped Enrollment in the study was prematurely terminated due to recruitment challenges and not due to concerns of safety for the participants.

Conditions

• Small Cell Lung Cancer

Interventions

• DRUG: M3814
• DRUG: Cisplatin
• DRUG: Etoposide

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

• [object Object]